Interferon Beta-1a Injection for MS from Japan
A recombinant interferon beta-1a formulation for relapsing multiple sclerosis treatment, regulating immune processes. Falls under HTS 3002.90.52.50 as an immunological product (interferon) prepared for therapeutic use via biotechnological methods. It reduces disease activity in neurological conditions.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Include recombinant DNA origin docs and bioequivalence studies for biologics approval
• Use validated cold chain with temperature excursions monitored for protein integrity
• Specify therapeutic dosing to distinguish from research cytokines